1ST Biotherapeutics is focused on developing innovative therapeutics to address significant unmet medical needs, particularly in the fields of neurodegenerative diseases, immuno-oncology, and rare diseases. The company is advancing a diverse portfolio of drug candidates that are currently in various stages of preclinical and clinical development. Their research emphasizes the use of advanced scientific and clinical expertise to create therapies that can improve patient outcomes. Notable candidates include FB-101, which targets the c-Abl pathway in Parkinson's disease, and FB849, aimed at enhancing immune responses in the tumor microenvironment for cancer treatment.

In addition to their drug candidates, 1ST Biotherapeutics is leveraging cutting-edge platform technologies to enhance their research and development efforts. Their AI Drug Discovery Engine integrates medicinal chemistry expertise with advanced artificial intelligence to streamline the drug development process. Furthermore, the company employs a targeted protein degradation platform, known as FINDER, to discover novel therapeutic approaches. This combination of innovative drug candidates and sophisticated platform technologies positions 1ST Biotherapeutics to make significant contributions to the treatment of complex diseases.

South Korea

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

1ST Biotherapeutics

Company Details